Recombinant Human CXCL14/BRAK Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 866-CX

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
866-CX-025
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

O95715

Conjugate

Unconjugated

Applications

Bioactivity

View all CXCL14/BRAK Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human CXCL14/BRAK protein
Ser35-Glu111

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser35

Predicted Molecular Mass

9.4 kDa

Activity

Measured by its ability to bind fluorescein-conjugated E. coli Bioparticles.
The ED50 for this effect is 1.5-7.5 μg/mL.

Formulation, Preparation and Storage

866-CX
Formulation Supplied as a 0.2 μm filtered solution in PBS.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: CXCL14/BRAK

CXCL14/BRAK (breast and kidney-expressed chemokine), also named MIP-2 gamma, KEC (kidney-expressed chemokine), and BMAC (B cell and monocyte-activating chemokine), is a member of CXC chemokine superfamily (1-5). The deduced 99 amino acid (aa) residue precursor has a 22 aa putative signal peptide that is cleaved to produce the 77 aa mature protein. Mature human and mouse CXCL14 differ by only 2 residues. Human CXCL14 shares approximately 30% aa sequence identity with MIP-2 alpha (GRO beta) as well as MIP-2 beta (GRO gamma). The gene for CXCL14 has been mapped human chromosome 5q31. Unlike the MIP-2 chemokines, CXCL14 lacks the ELR domain preceding the CXC motif. CXCL14 transcripts are constitutively expressed at high levels in the basal layer of epidermal keratinocytes and dermal fibroblasts of skin tissues as well as lamina propria cells in normal intestinal tissues. CXCL14 has been shown to be a highly selective chemoattractant for monocytes that have been treated with prostaglandin E2 or forskolin, agents that activate adenylate cyclase. CXCL14 has been proposed to be important for regulating the trafficking of macrophage precursor to regions in skin and mucosal tissues that support their development. Consistent with this hypothesis, macrophages were frequently found to co-localize with CXCL14-producing cells in the dermis and lamina propria.

References

  1. Hromas, R. et al. (1999) Biochem. Biophys. Res. Commun. 255:703.
  2. Cao, X. et al. (2000) J. Immunol. 165:2588.
  3. Kurth, I. et al. (2001) J. Exp., Med. 194:855.
  4. Frederick, M.J. et al. (2000) Am. J. Pathol. 156:1937.
  5. Sleeman, M.A. et al. (2000) Int. Immunol. 12:677.

Alternate Names

Bolekine, BRAK, CXC-X3

Entrez Gene IDs

9547 (Human); 57266 (Mouse)

Gene Symbol

CXCL14

UniProt

O95715

Additional CXCL14/BRAK Products

Product Documents for Recombinant Human CXCL14/BRAK Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human CXCL14/BRAK Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.